A groundbreaking advance in diabetes treatment has emerged, with a 25-year-old woman reportedly achieving a functional cure for type 1 diabetes through an innovative stem cell therapy. For over a year, she has maintained insulin independence, signaling a potential shift in the management of this autoimmune disease.
Type 1 diabetes occurs when the immune system attacks insulin-producing beta cells in the pancreas, leading to an inability to regulate blood glucose levels and necessitating lifelong insulin injections. The new therapy addresses this issue by utilizing the patient’s own stem cells to regenerate insulin-producing cells.
The recent phase I clinical trial yielded promising results, demonstrating the feasibility of replacing lost insulin-producing cells with newly cultivated ones. The woman, diagnosed with type 1 diabetes 11 years ago, had previously endured two liver transplants and a pancreas transplant due to her condition.
In this trial, researchers extracted stem cells from her adipose tissue and chemically induced them to revert to a pluripotent state, allowing for differentiation into various cell types, including pancreatic islet cells. These newly formed cells were then cultivated and transplanted into her abdominal muscles.
Post-transplant, the patient was closely monitored for a year. Remarkably, her insulin requirements began to decline within two weeks, and by the 75th day, she achieved complete insulin independence. Throughout the study, she remained within a healthy glycemic range for over 98% of the time, with no reported complications from the transplant.
This study marks a significant departure from previous research in several key areas. Unlike earlier trials that utilized genetic methods to induce stem cells, this approach employs chemical induction and taps into a different source of stem cells within the body. Additionally, the choice to implant the cells in the abdominal muscles rather than the liver has improved the survival and maturation rates of the cells while also reducing invasiveness.
However, the therapy does carry a caveat: the patient’s immune system must still be suppressed to prevent rejection of the new cells, as the underlying autoimmune response remains unaddressed. This necessity aligns with standard practices in organ and tissue transplantation.
Overall, the trial indicates that this stem cell therapy could represent a promising avenue for type 1 diabetes treatment, pending further investigation. Currently, two additional participants are enrolled in the ongoing trial, and the findings were published in the scientific journal .
Related topics:
Bariatric Surgery Shown to Better Preserve Kidney Function Than GLP-1 Drugs
Study Sheds Light on Non-Diabetic Kidney Disease Factors in Diabetic Patients
Semaglutide Linked to Reduced Opioid Overdose Risk in Diabetic Patients
